Acurx Pharmaceuticals Reports Q1 2026 Financial Results with $1.68 Million Net Loss

Acurx Pharmaceuticals, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $1.68 million, a decrease from the $2.15 million loss recorded in the same period of the previous year. The company's total operating expenses for the quarter were $1.72 million, down 21% from $2.18 million in the first quarter of 2025. This reduction was primarily driven by a 43% decrease in research and development expenses, which fell to $341,468 from $598,798, and a 13% decline in general and administrative expenses, which decreased to $1.37 million from $1.58 million.

In terms of liquidity, Acurx reported cash and cash equivalents of approximately $9.25 million as of March 31, 2026, an increase from $7.56 million at the end of 2025. The company’s working capital stood at $7 million, reflecting a solid financial position to support ongoing operations. The increase in cash was attributed to financing activities, which generated $3.11 million during the quarter, primarily from the equity line of credit purchase agreement with Lincoln Park Capital Fund, LLC.

Strategically, Acurx is focused on advancing its lead antibiotic candidate, ibezapolstat, which targets Clostridium difficile infections. The company has initiated a new clinical development initiative to expand the ibezapolstat program into recurrent C. difficile infections, with plans for a pilot trial to enroll up to 20 patients. This follows positive results from previous clinical trials, where ibezapolstat demonstrated a 96% clinical cure rate in patients with C. difficile infections. The company aims to leverage these results to inform the design of a planned Phase 3 registration trial.

Operationally, Acurx has not generated any revenue since its inception and continues to rely on equity financing to fund its operations. The company has raised approximately $12.9 million from various equity offerings since its inception, with a significant portion coming from its initial public offering in June 2021. As of March 31, 2026, Acurx had a total accumulated deficit of approximately $77 million, indicating the ongoing financial challenges typical for clinical-stage biopharmaceutical companies.

Looking ahead, Acurx management anticipates continued operating losses as it advances its clinical programs and seeks regulatory approvals. The company plans to pursue additional equity financing to support its operations, although it acknowledges the uncertainty surrounding the availability of such funding. The outlook remains cautious, with management emphasizing the need for further capital to sustain operations and achieve its long-term objectives in antibiotic development.